Product/Composition:- | Telmisartan tablets |
---|---|
Strength:- | 20 mg, 40 mg, 80 mg |
Form:- | Tablets |
Reference Brands:- | Micardis(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Telmisartan is an angiotensin II receptor blocker (ARB) that relaxes blood vessels by blocking angiotensin II effects. It lowers blood pressure, reduces stroke risk, and supports heart and kidney health. Benefits include effective hypertension control, cardiovascular protection, and improved long-term outcomes for patients with high blood pressure and related conditions.
Telmisartan tablets, marketed as Micardis, are approved in both the US by the FDA and in the EU via EMA for hypertension and cardiovascular risk reduction. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional regulations supports swift approval, safe use, and worldwide availability, helping manage hypertension and improve cardiovascular outcomes.